News & Updates
Filter by Specialty:
Ribociclib plus endocrine therapy: A win for early breast cancer?
In the second interim efficacy analysis of the phase III NATALEE trial, a combination regimen comprising the CDK4/6 inhibitor ribociclib and endocrine therapy (ET) demonstrated favourable signals for the adjuvant treatment of stage II/III hormone receptor-positive, HER2-negative (HR+, HER2–) early breast cancer.
Ribociclib plus endocrine therapy: A win for early breast cancer?
16 Jun 2023
Add-on myoinositol helps with menstrual period regularity in women with PCOS
In the treatment of women with polycystic ovary syndrome (PCOS), adding myoinositol to metformin provides further benefits for improving the regularity of menstrual cycle, with subsequent gains in quality of life, according to a study.
Add-on myoinositol helps with menstrual period regularity in women with PCOS
12 Jun 2023
Pazopanib plus chemo improves response but not survival in advanced ovarian cancer
Treatment with pazopanib combined with chemotherapy leads to better overall response rate (ORR) in patients with recurrent or persistent ovarian cancer but falls short of improving survival, reveals a study. In addition, the combination therapy contributes to an increase in several adverse events (AEs).
Pazopanib plus chemo improves response but not survival in advanced ovarian cancer
08 Jun 2023
Fruit and vegetable intake lowers endometrial cancer risk
Eating fruits and vegetables may help reduce the risk of endometrial cancer, suggests a recent study, noting that specific kinds of fruits and vegetables must be recommended based on their outstanding bioactive components.
